News from agenus A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 29, 2020, 08:00 ET ASCO Presentation of Agenus' AGEN1181 by Dr. Steven O'Day

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and...


Feb 06, 2020, 15:12 ET Agenus Announces Investor Day on February 20, 2020

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today...


Dec 19, 2019, 07:30 ET Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer...


Nov 04, 2019, 07:00 ET Agenus Provides Corporate Update with Third Quarter 2019 Financial Results

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1, and cancer...


Sep 30, 2019, 16:34 ET Agenus to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer...


Aug 06, 2019, 10:56 ET Agenus to Report Second Quarter 2019 Financial Results on August 8, 2019 and Host Conference Call and Webcast

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its second...


May 03, 2019, 13:38 ET Agenus to Report First Quarter 2019 Financial Results on May 9, 2019 and Host Conference Call and Webcast

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell...


Mar 21, 2019, 09:00 ET Agenus Announces Clinical Appointments

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell...


Mar 14, 2019, 08:00 ET Agenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell...


Feb 19, 2019, 08:30 ET Agenus Launches First Asset-Backed Digital-Security Offering in Healthcare

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive ...


Jan 03, 2019, 11:30 ET Agenus Awarded Grant to Enable QS-21 Innovations

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive ...


Dec 20, 2018, 07:30 ET Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies

Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O)...


Nov 13, 2018, 16:05 ET Agenus Elects New Board Member Dr. Allison Jeynes-Ellis and Appoints Chief Operating Officer Dr. Jennifer Buell

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell...


Jun 06, 2018, 01:00 ET Agenus to Present at the Jefferies 2018 Global Healthcare Conference in New York, NY

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell...


Jan 22, 2018, 10:00 ET Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the...


Jan 22, 2018, 07:00 ET Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty Partners

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the...


Nov 15, 2017, 08:25 ET Agenus Receives License Fee of $4 Million USD from Merck

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the ...


Nov 09, 2017, 07:45 ET Agenus To Present on Lead Antibody Programs AGEN1884 (CTLA-4) and AGEN2034 (PD-1) at SITC 2017

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced that data ...


Nov 07, 2017, 08:22 ET Agenus Reports Third Quarter 2017 Financial Results and Provides Corporate Update

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a...


Oct 26, 2017, 12:40 ET Agenus to Report Third Quarter 2017 Financial Results on November 7, 2017 and Host Conference Call and Webcast

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its third...


Oct 20, 2017, 19:00 ET FDA Approves GSK's Shingles Vaccine with Agenus' QS-21 Stimulon® Adjuvant

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that the...